证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-024 江苏鱼跃医疗设备股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票方式、网络投票方式 3、会议召开时间： 现场会议时间：2025年5月16日下午13:30 网络投票时间：2025年5月16日 7、出席情况 本次股东大会采取现场投票与网络投票相结合的方式进行投票表决。出席本次股东 大会的股东及股东授权委托代表共计449人，参加股东大会投票的股东及股东授权委托 代表共计449人，代表有表决权股份数599,820,406股，占公司有表决权股份总数（公司总 股份数1,002,476,929股）的59.8338%，其中： 通过深圳证券交易所交易系统进行网络投票的时间为2025年5月16日9:15~9:25， 9:30~11:30，13:00~15:00； 通过深圳证券交易所互联网投票系统 ...

Core Insights - The aging population, scarcity of grassroots medical resources, and uneven distribution of quality medical resources are driving the rapid integration and application of AI technology in the healthcare sector [2] - AI medical technology is expected to reconstruct the medical value chain, creating a new model for equitable access to medical resources [5] - The domestic AI medical market is projected to reach 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [7] Industry Overview - The aging population in China is expected to reach 310 million by the end of 2024, accounting for 22% of the total population, and is projected to exceed 400 million by 2035, surpassing 30% [2] - Grassroots medical institutions account for 94.9% of all medical institutions in China but only handle 51.8% of the total medical services, indicating a mismatch in resource utilization and service quality [2] - AI technology is being rapidly integrated across various medical processes, including imaging diagnosis, surgical assistance, drug development, and intelligent management [2] AI Medical Technology - AI medical technology enhances the quality and efficiency of healthcare services by providing intelligent management and optimization of medical processes [3] - AI medical devices can be categorized into two types: those that include hardware (e.g., diagnostic analysis systems, robots) and those that operate as standalone software [3] - The advantages of AI in healthcare include high efficiency, accuracy, and low misdiagnosis rates, which can significantly improve diagnostic processes and treatment timelines [4] Market Potential - The AI medical market is expanding rapidly, with significant applications in drug and vaccine development, medical imaging analysis, smart hospital management, and genomics research [7] - AI applications in in-vitro diagnostics are expected to grow at a compound annual growth rate of 26.1% by 2028 [17] Company Profiles - Mindray Medical (300760) has a comprehensive product line in life information and support, in vitro diagnostics, and medical imaging, with a projected revenue of 36.725 billion yuan in 2024, a 5.14% increase year-on-year [10] - United Imaging (688271) focuses on medical imaging equipment and has been investing in AI since 2017, with a projected revenue of 10.3 billion yuan in 2024, a 9.73% decrease year-on-year [14] - BGI Genomics (300676) specializes in genomic testing services and is expected to generate 3.867 billion yuan in revenue in 2024, an 11.10% decrease year-on-year [19] - Yuyue Medical (002223) is a leading provider of medical devices, with a projected revenue of 7.566 billion yuan in 2024, a 5.09% decrease year-on-year [23] - Kefu Medical (301087) focuses on home medical devices and is expected to achieve 2.983 billion yuan in revenue in 2024, a 4.53% increase year-on-year [25]

Group 1 - A total of 66 buy ratings were issued by institutions today, covering 65 stocks, with Dongshan Precision receiving the highest attention with 2 buy ratings [1] - Among the stocks rated, 23 provided future target prices, with 19 stocks showing an upside potential of over 20%, led by Luzhou Laojiao with a potential increase of 62.32% [1] - The average increase for stocks rated as buy today was 0.46%, outperforming the Shanghai Composite Index, with notable gainers including Yinlun Co., Longsheng Technology, and Zhongji Xuchuang [1][2] Group 2 - The pharmaceutical and biological industry was the most favored, with stocks like Yuyue Medical and Changchun Gaoxin making the buy rating list, while the power equipment and electronics sectors also attracted attention with 8 stocks each [2] - The stocks with buy ratings included a diverse range of industries, such as electronics, power equipment, and pharmaceuticals, indicating broad institutional interest [3][4] - Specific stocks like Luzhou Laojiao and Changchun Gaoxin were highlighted for their strong performance and potential, with the former showing a significant upside in target price [1][4]

Core Viewpoint - The medical device industry in 2024 faces a complex policy environment and market challenges, with a slight revenue growth of 0.19% but a significant decline in net profit by 13.82%, indicating a divergence in performance across different sub-sectors [1][13]. Medical Equipment - The medical equipment sector experienced a revenue decline of 1.38% and a net profit drop of 17.93% in 2024, with Q1 2025 showing a further revenue decrease of 5.27% and a net profit decline of 14.10% [3][10]. - The decline is attributed to slowed bidding processes and inventory digestion, particularly affecting imaging and monitoring equipment [3][4]. - Leading company, United Imaging Healthcare, reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73%, marking the first decline in net profit in six years [3][4]. High-Value Consumables - The high-value consumables sector saw a revenue growth of 3.58% but a net profit decline of 4.09% in 2024, with Q1 2025 showing a slight revenue increase of 0.25% and a net profit drop of 6.15% [6][7]. - The sector is impacted by price pressures from national procurement policies, but domestic market share for local brands is improving [6][7]. Low-Value Consumables - The low-value consumables sector achieved a revenue growth of 12.86% and a remarkable net profit increase of 114.83% in 2024, with Q1 2025 showing a revenue growth of 2.37% and a net profit growth of 7.19% [8][9]. - The growth is driven by recovery in the domestic market and accelerated international expansion, particularly in mid-to-high-end markets [8][9]. In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 6.13% and a net profit drop of 47.04% in 2024, with Q1 2025 showing a further revenue decrease of 15.39% and a net profit decline of 40.27% [10][11]. - The decline is largely due to the high base effect from the COVID-19 pandemic and the impact of various policies, including DRGs and procurement policies [10][11]. Conclusion - The overall revenue growth in the medical device industry is stable, but profit volatility is significant, particularly in the in vitro diagnostics and medical equipment sectors. However, growth drivers remain in low-value consumables' international expansion and innovation, high-value consumables' technological updates, and the gradual recovery of medical equipment [13][14].

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

Market Overview - On May 15, major market indices collectively declined, with the Shanghai Composite Index falling by 0.68% and the ChiNext Index dropping nearly 2% [1] - The total trading volume in A-shares reached 1.19 trillion yuan, with over 1,400 stocks closing higher, including 78 stocks hitting the daily limit [1] Sector Performance - The beauty and personal care sector led the gains, closing up 3.68%, with stocks like Qingsong Co., Huaye Fragrance, and Jieya Co. hitting the daily limit [1] - The port and shipping sector experienced a pullback after an initial rise, with stocks such as Nanjing Port and Ningbo Maritime continuing to hit the daily limit [1] - The synthetic biology concept index rose over 2%, with 10 stocks hitting the daily limit, including Chuaning Biology and Meinong Biology [1] Historical Highs - A total of 28 stocks reached historical closing highs, with the beauty and personal care, banking, and machinery sectors showing significant concentration [2] - The average increase for stocks that reached historical highs was 6.87%, with notable gainers including Babi Co., Dengkang Oral, and Ruoyuchen [2] Institutional Trading - On May 15, 14 stocks faced net selling by institutions exceeding 10 million yuan, with Youfu Co. leading the sell-off at 146 million yuan [4] - Only 8 stocks saw net buying from institutions, with Aerospace Nanhu and Yuzhong Three Gorges A receiving over 10 million yuan in net purchases [4] Northbound Capital Flow - Northbound capital saw net buying in 5 stocks, with Jilin Chemical Fiber leading at 33.01 million yuan, followed by Jingyun Tong at 28.59 million yuan [6] - Aerospace Nanhu experienced the highest net selling among northbound funds, amounting to 50.41 million yuan [6] Company Announcements - Feilong Co. received a project designation notice from a well-known domestic automotive brand, becoming a supplier for a thermal management module [7] - Yuyue Medical's automatic external defibrillator (AED) product obtained EU MDR certification [8] - Heng Rui Pharmaceutical completed a share repurchase of 12.90 million shares, accounting for 0.2% of its total share capital, with a total transaction amount of 601 million yuan [8]

Group 1: Hainan Airlines - Hainan Airlines reported a 10.33% year-on-year increase in revenue passenger kilometers for April [1] - The group's passenger capacity input increased by 10.32% year-on-year [1] - Cargo and mail volume increased by 23.20% year-on-year, with cargo mail revenue ton-kilometers up by 41.04% [1] Group 2: Heng Rui Medicine - Heng Rui Medicine completed a share buyback, repurchasing 12.9051 million shares for a total of 601 million yuan [2] - The shares repurchased represent 0.2% of the company's total share capital, with an average buyback price of approximately 46.59 yuan per share [2] Group 3: China Shenhua - China Shenhua's coal sales volume in April decreased by 4% year-on-year, totaling 35.6 million tons [6] - The company's total electricity generation fell by 9.9% year-on-year [6] Group 4: China National Aviation - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April [8] - The average passenger load factor reached 81.3%, up 2.5 percentage points year-on-year [8] Group 5: Yuyue Medical - Yuyue Medical's subsidiary received EU MDR certification for its automated external defibrillator (AED) product [9] Group 6: Hubei Yihua - Hubei Yihua's controlling shareholder plans to increase its stake in the company by 200 million to 400 million yuan [12] Group 7: Other Companies - Chengdi Xiangjiang signed a contract for a data center project with a total value of 1.632 billion yuan [3] - Jingyuan Environmental Protection's subsidiary signed a contract for a computing cluster construction project worth 365 million yuan [4]

二、对公司的影响 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-023 江苏鱼跃医疗设备股份有限公司 关于自动体外除颤器（AED）产品获得欧盟 MDR 认证的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"公司"）控股子公司之孙公司 Metrax GmbH 近日收到了 TÜV SÜD Product Service GmbH 的通知，Metrax GmbH 申请的自动体外除颤器（以下简称"AED"）获得符合欧盟《医疗器械第 2017/745 号法规》（Medical Devices Regulation（EU）2017/745，简称"MDR"）要求的 III 类医疗器械 CE 认证证书，现将具体情况公告如下： | 产品名称 | Automated External Defibrillator 自动体外除颤器（AED） | | --- | --- | | 制造商名称 | Metrax GmbH | | 证书编号 | G70 023787 0039 Rev. 00 | | 分类 | III 类 | | 证 ...

Group 1 - Yuyue Medical (002223) announced that its subsidiary Metrax GmbH has received CE certification for its automated external defibrillator (AED) in compliance with the EU Medical Devices Regulation (EU) 2017/745 [1] - The CE certificate number is G700237870039Rev.00, and it is valid from May 12, 2025, to May 11, 2030 [1] - The device is designed for suspected sudden cardiac arrest situations, guiding operators to initiate resuscitation, analyze the patient's electrocardiogram (ECG), and provide defibrillation treatment when a shockable rhythm is detected [1]

Core Viewpoint - Yuyue Medical (002223.SZ) announced that its subsidiary Metrax GmbH's automated external defibrillator (AED) product has obtained CE certification as a Class III medical device in accordance with the EU Medical Device Regulation 2017/745, which enhances the company's competitive edge in the global emergency medical market, particularly in EU countries and other nations recognizing EU MDR certification [1] Group 1 - The AED product represents the latest generation of intelligent products from the company, showcasing significant technological advantages and market competitiveness [1] - The CE certification will facilitate the company's emergency business operations in the global market [1] - The focus on EU countries and other nations that recognize EU MDR certification indicates a strategic expansion plan for the company's product offerings [1]